.Attributes Medicine, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medication conjugate (ADC) tisotumab vedotin resulted in enhanced progression-free and general survival, bring about FDA approval and also a brand new procedure option for patients.